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Abstract 
Kisspeptins are G protein-coupled receptor ligands originally identified as human metastasis 
suppressor gene products that have the ability to suppress melanoma and breast 
cancer metastasis and recently found to have an important role in initiating secretion of 
gonadotropin-releasing hormone (GnRH) at puberty.  In the brain the gene is transcribed 
within the hippocampal dentate gyrus. Kisspeptin-13 is one of endogenous isoforms that 
consists of 13 amino acids. Antidepressive-like effects of kisspeptin-13 was studied and the 
involvement of the adrenergic, serotonergic, cholinergic, dopaminergic or gabaergic receptors 
in its antidepressant-like effect was investigated in modified forced swimming test (FST) in 
mice. Mice were pretreated with a non-selective α-adrenergic receptor antagonist 
phenoxybenzamine, an α1/α2β-adrenergic receptor antagonist, prazosin, an α2-adrenergic 
receptor antagonist, yohimbine, a β-adrenergic receptor antagonist, propranolol, a mixed 5-
HT1/5-HT2 serotonergic receptor antagonist, methysergide, a non-selective 5-
HT2 serotonergic receptor antagonist, cyproheptadine, nonselective muscarinic acetylcholine  
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receptor antagonist, atropine, D2,D3,D4 dopamine receptor antagonist, haloperidol or γ-
aminobutyric acid subunit A (GABAA) receptor antagonist, bicucullin. 
FST showed that kisspeptin-13 reversed the immobility, climbing and swimming times, 
suggesting antidepressant-like effects. Phenoxybenzamine, yohimbine and cyproheptadine 
prevented the effects of kisspeptin-13 on the immobility, climbing and swimming time. 
Prazosin, propranolol, methysergide, atropine, haloperidol and bicucullin did not change the 
effects of kisspeptin-13. 
The results demonstrated that the antidepressant-like effect of kisspeptin-13 is mediated, at 
least in part, by an interaction of the α2-adrenergic and 5-HT2 serotonergic receptors in a 
modified mouse FST. 
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1. Introduction 
Kisspeptin, formerly known as metastin was originally identified as a human metastasis 
suppressor that inhibits metastasis of melanoma and breast cancer [1].  This G protein-
coupled receptor ligand was recently found to have an important role in initiating secretion of 
gonadotropin-releasing hormone (GnRH) at puberty [2]. In central nervous system kisspeptin 
is transcribed within the hippocampal dentate gyrus. Kisspeptin-13 is one of endogenous 
isoforms that consists of 13 amino acids [3]. However, little is know about the machanisms 
and pathways of kisspeptin-13 on brain functions. 
Antidepressive-like effects of kisspeptin-13 was studied and the involvement of the 
adrenergic, serotonergic, cholinergic, dopaminergic or gabanergic receptors in its 
antidepressant-like effect was investigated in modified forced swimming test (FST) in mice. 
Mice were pretreated with a non-selective α-adrenergic receptor antagonist 
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phenoxybenzamine, an α1/α2β-adrenergic receptor antagonist, prazosin, an α2-adrenergic 
receptor antagonist, yohimbine, a β-adrenergic receptor antagonist, propranolol, a mixed 5-
HT1/5-HT2 serotonergic receptor antagonist, methysergide, a non-selective 5-
HT2 serotonergic receptor antagonist, cyproheptadine, nonselective muscarinic acetylcholine 
receptor antagonist, atropine, D2,D3,D4 dopamine receptor antagonist, haloperidol or γ-
aminobutyric acid subunit A (GABAA) receptor antagonist, bicucullin. 
2. Materials and methods 
2.1. Animals 
CFLP male mice were kept and handled during the experiments in accordance with the 
instructions of the University of Szeged Ethical Committee for the Protection of  
 
Animals in Research. Each animal was used in the experiments only once. The animals were 
housed in cages in a room maintained at constant temperature (25 ± 1 °C) and on a 12-h dark–
light cycle (lights on at 06:00–18:00 h) with free access to tap water and standard laboratory 
food. At least 1 week of recovery from  
surgery was allowed before the experiments. 
2.2. Surgery 
The mice were implanted with a cannula introduced into the right lateral brain ventricle in 
order to allow intracerebroventricular (i.c.v.) administration. The polystyrene cannula was 
inserted stereotaxically into the ventricle at the coordinates 0.2 mm posterior, 0.2 mm lateral 
to the bregma, and 2.0 mm deep from the dural surface [4]. The cannula was secured with 
cianoachrilate (Ferrobond) (Budapest, Hungary). The mice were allowed a minimum of 5 
days to recover from surgery before any i.c.v. administration. 
2.3. Materials 
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Kisspeptin-13 was from Bachem (Basel Switzerland).  Phenoxybenzamine hydrochloride was 
obtained from Smith Kline & French (Herts, UK); prazosin hydrochloride fromTocris (); 
yohimbine hydrochloride from Tocris (Cologne, Germany); propranolol hydrochloride from 
ICI Ltd. (Macclesfield, UK); methysergide hydrogen maleate from Sandoz (Cologne, 
Germany); cyproheptadine hydrochloride from Tocris (Bristol, UK); atropine sulphate from 
EGYS (Budapest, Hungary); haloperidol from G. Richter (Budapest, Hungary); and 
bicuculline methiodide from Sandoz (Basle, Switzerland). 
Kisspeptin-143 was lyophilized in a quantity of 10 µg per ampoule and stored at −20 °C. 
Immediately before the experiments. kisspeptin-143 was dissolved in sterile pyrogen-free 
0.9% saline and administered i.c.v. via the cannula in a volume of 2 µl. 
2.4. Forced swimming test 
The modified mouse FST was conducted as reported previously [5,6]. The mice were forced 
to swim individually in a glass cylinder 12 cm in diameter and 30 cm in height, filled with 
water to a height of 20 cm. The temperature of the water was adjusted to 25 ± 1 C. The water 
was changed between the individual mice. A 15min pretest session was followed 24 h later by 
a 5min test session. Phenoxybenzamine (2mg/kg,i.p.), prazosin (62.5 µg/kg,i.p.), yohimbine 
(5mg/kg,i.p.),propranolol (5mg/kg, i.p.), methysergide (5mg/kg, i.p.), cyproheptadine 
(3mg/kg, i.p.), atropine (2mg/kg, i.p.), haloperidol (10 µg/kg, i.p.) or bicuculline (2mg/kg, 
i.p.) were administered 1 h before the test session followed30min later by kisspeptin (2.0 µg/2 
µl, i.c.v.) [7–12]. Physiological saline was used as vehicle control. A time-sampling technique 
was applied to score the durations of climbing, swimming and immobility. Climbing time was 
measured when the mouse was participating inactive vertical motion with 
its forelegs above the water level; swimming time was recorded when the mouse was moving 
in horizontally on the surface of the water; and immobility time was registered when the 
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mouse was in a upright position on the surface with its front paws together and making only 
those movements necessary to keep itself afloat. 
2.5. Statistical analysis 
The analysis of variance (ANOVA) test was followed by Tukey’s test for multiple 
comparisons with unequal cell size. Probability values (P) of less than 0.05 were regarded as 
indicative of significant differences. 
3. Results 
Kisspeptin-13 (2.0 µg/2 µl)-administered mice exhibited a significantly decreased immobility 
time [F(3.35) = 14.98: P < 0.05], a significantly increased climbing time 
[F (3.35) = 7.75: P < 0.05] and a significantly increased swimming time 
[F (3.35) = 11.10: P < 0.05] (Fig. 1). 
Phenoxybenzamine per se (2mg/kg) did not affect the immobility time, climbing time, or 
swimming time. In kisspeptin-13-treated mice, pretreatment with phenoxybenzamine partially 
reversed the kisspeptin-13-induced change in the immobility time, and decreased the changes 
in the climbing and swimming times (Fig. 2).  
Prazosin per se (62.5 µg/kg, i.p.) did not affect the immobility time, the climbing time or the 
swimming time. In kisspeptin-13-treated mice, pretreatment with prazosin did not reverse the 
kisspeptin-13-induced change in the immobility time, climbing time and the swimming time 
(data not shown). 
Yohimbine per se (5mg/kg, i.p.) did not affect the immobility time, the climbing time, or the 
swimming time. In kisspeptin-13-treated mice, pretreatment with yohimbine partially reversed 
the immobility time, climbing time and the swimming time (Fig. 3). 
Methysergide per se (5mg/kg, i.p.) did not affect the immobility time, the climbing time or the 
swimming time. In kisspeptin-13-treated mice, pretreatment with methysergide did not 
reverse immobility time, the climbing time and the swimming time (data not shown). 
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Cyproheptadine per se (3mg/kg, i.p.) did not affect the immobility time, the climbing time or 
the swimming time. In kisspeptin-13-treated mice, pretreatment with cyproheptadine resulted 
in an increased immobility time and decreased the changes 
in the climbing and the swimming times (Fig. 4). 
Propranolol per se (5mg/kg, i.p.) did not affect the immobility time, the climbing time,  
or the swimming time. In kisspeptin-13- treated mice time, pretreatment with propranolol did 
not lead to an increase in the immobility time, and did not affect the climbing time ort he 
swimming time (data not shown). 
Atropine per se (2mg/kg, i.p.) did not affect the immobility time, the climbing time, or the 
swimming time. In kisspeptin-13-treated mice, pretreatment with atropine did not affect the 
increased immobility time and the decreased climbing and the swimming times (data not 
shown). 
Haloperidol per se (10 µg/kg, i.p.) did not affect the immobility time, the climbing time, or the 
swimming time. In kisspeptin-13-treated mice, pretreatment with haloperidol did not increase 
the immobility time nor affect the climbing or the swimming times (data not shown). 
Bicuculline per se (2mg/kg, i.p.) did not affect the immobility time, the climbing time or the 
swimming time. In kisspeptin-13-treated mice pretreatment with bicuculline did not increase 
the immobility time, or the climbing time, or the swimming time (data not shown). 
The above results reveal that the antidepressant-like effect of kisspeptin-13 is mediated, at 
least in part, by α2-adrenergic receptors and 5-HT2 serotonergic receptors in a modified mouse 
FST. 
4. Discussion 
In the central nervous system kisspeptin expressing neurons are located in the anteroventral 
periventricular nucleus (AVPV), perventricular nucleus (PVN), anterodorsal preoptic nucleus 
(ADP) and arcuate nuceus (Arc) [13].  In a close relationship to PVN, the neurons of AVPV 
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and Arc project fibers into the preoptic area rich in GnRH cell bodies.  It is now known that 
kisspeptin stimulates the secretion of GnRH which is sensitive to steroid levels [14].  The 
previous studies showed that luteinizing hormone releasing hormone (LHRH) antagonist, 
cetrorelix and growth hormone releasing hormone (GHLH) antagonist kisspeptin-13 have 
antidepressant-like effects in a modified mice FST, suggesting close relationships between 
growth hormone reguation and mood disorders alleviation [15,16,17,18]. 
Kisspeptin-13 is one of endogenous kisspeptin isoforms that consists of 13 amino acids. In 
this study kisspeptin-13 display antidepressnat-like effects in a modified FST.  
To clarify the mechanism of the antidepressant-like actions of kisspeptin-13, various receptor 
blockers were applied berfore kisspeptin-13 administration. The doses of receptor blockers 
were selected so that blockers per se were ineffective but were able to block the action of a 
neuropeptide as describe in the previous study [19]. The obervation with receptor blockers 
indicates that the action of kisspeptin-13 is mediated by certain receptors. 
The results indicated a non-selective α-adrenergic receptor antagonist, phenoxybenzamine, an 
α2-adrenergic receptor antagonist, yohimbine and a non-selective 5-HT2 serotonergic receptor 
antagonist, cyproheptadine prevented the effects of kisspeptin-13 on the immobility, climbing 
and swimming time. an α1/α2β-adrenergic receptor antagonist, prazosin, a β-adrenergic 
receptor antagonist, propranolol, a mixed 5-HT1/5-HT2 serotonergic receptor antagonist, 
methysergide, a nonselective muscarinic acetylcholine receptor antagonist, atropine, D2,D3,D4 
dopamine receptor antagonist, haloperidol and γ-aminobutyric acid subunit A (GABAA) 
receptor antagonist, bicucullin did not change the effects of kisspeptin-13. 
The results demonstrated that the antidepressant-like effect of kisspeptin-13 is mediated, at 
least in part, by an interaction of the α2-adrenergic and 5-HT2 serotonergic receptors in a 
modified mouse FST. 
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Figure 1. The antidepressant-like effects of kisspeptin-13 in modified mouse forced swim 
test (FST).  
Control (N=12), kisspeptin-13 0.5 µg/2 µl, i.c.v. (N=6), kisspeptin-13 1.0 µg/2 µl, i.c.v. 
(N=12), kisspeptin-13 2.0 µg/2 µl, i.c.v.  (N=5). x: P < 0.05 vs. control (N: the number of 
animals, P: probability). 
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Figure 2. The effect of a nonselective α-adrenergic receptor antagonist, 
phenoxybenzamine (POB) in kisspeptin-13-induced antidepressant-like action in 
modified mouse forced swim test (FST). 
Control (N=5), kisspeptin-13 2.0 µg/2 µl, i.c.v. (N=5), Phenoxybenzamine (POB) 2.0 mg/kg, 
i.p. (N=5), Phenoxybenzamine (POB) 2.0 mg/kg, i.p. + kisspeptin-13  2.0 µg /2 µl, i.c.v. 
(N=5). x: P < 0.05 vs. control (N: the number of animals, P: probability). 
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Figure 3. The effect of a nonselective α-adrenergic receptor antagonist, yohimbine 
(YOH) in kisspeptin-13-induced antidepressant-like action in modified mouse forced 
swim test (FST).  
Control (N=10), kisspeptin-13 2.0 µg/2 µl, i.c.v. (N=10), yohimbine (YOH) 5.0 mg/kg, i.p. 
(N=10), yohimbine (YOH) 5.0 mg/kg, i.p. + kisspeptin-13  2.0 µg /2 µl, i.c.v. (N=10). x: P < 
0.05 vs. control (N: the number of animals, P: probability). 
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Figure 4. The effect of a nonselective 5-HT2 serotonergic  receptor antagonist, 
cyproheptadine (CPH) in kisspeptin-13-induced antidepressant-like action in modified 
mouse forced swim test (FST).  
Control (N=14), kisspeptin-13 2.0 µg/2 µl, i.c.v. (N=15), Cyproheptadine (CPH) 3.0 mg/kg, 
i.p. (N=15), Cyproheptadine (CPH) 3.0 mg/kg, i.p. + kisspeptin-13 2.0 µg /2 µl, i.c.v. (N=15). 
x: P < 0.05 vs. control (N: the number of animals, P: probability). 
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